RxDoctor Payments Data

Mujahed Abbas, MD

Critical Care Medicine · Lansing, MINPI 1861500894

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,556 of the $27,902 with a category attached, or 77.3%. Melinta Therapeutics, LLC accounts for 89.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $10,240 and has fallen 94.0% since, to $619 in 2025. Among critical care medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,902in general payments, 2019–2025

Across 283 payments — averaging $98.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Melinta Therapeutics, LLC$25K
  • Insmed, Inc.$1K
  • Gilead$558
  • Viiv Healthcare Company$302
  • Paratek Pharmaceuticals, Inc.$205
  • Merck$158
  • plus $628 from 11 others

What the payments were for

  • Consulting fees$7503%
  • Speaking & faculty fees$21,55677%
  • Travel & lodging$1,2344%
  • Food & beverage$4,03514%
  • Education$3281%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,902 in reported general payments places this provider in the 95th percentile of 177 critical care medicine providers in Michigan.

See all critical care medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$616,138
Medicare patients
385
Services billed
42,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala12$49,669
ErtapenemErtapenem Sodium35$16,773
Daptomycin42$13,400
Vancomycin Hcl72$7,659
Itraconazole23$5,683
CeftriaxoneCeftriaxone Sodium109$5,252
Cefepime Hcl36$5,151
Ampicillin Sodium16$3,955
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam16$2,940
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim35$1,483
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav54$1,321
Cephalexin32$779
Cefazolin Sodium29$734
Fluconazole11$617
Linezolid12$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$558$49,66912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 critical care medicine providers in Michigan.

Other critical care medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →